Safety and Toxicity Profiles of CAR T Cell Therapy in Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis

The application of CD19-directed chimeric antigen receptor T (CAR T) cell therapy has improved outcomes for thousands of patients with non-Hodgkin B cell lymphoma (NHL). The toxicities associated with various CAR T cell products, however, can be severe and difficult to anticipate.

Source: Clinical Lymphoma, Myeloma and Leukemia - February 16, 2024 Category: Hematology Authors: Samuel Yamshon, Caitlin Gribbin, Mohammad Alhomoud, Nora Chokr, Zhengming Chen, Michelle Demetres, Michelle Pasciolla, John Leonard, Tsiporah Shore, Peter Martin Tags: Original Study Source Type: research